Core Insights - Scientific Industries, Inc. reported a 15% year-over-year increase in sales from its Torbal Division, contributing to a 52.2% rise in net revenues for Q3 2025 compared to Q3 2024 [1][6][8] - The company launched its first AI-powered feature for the VIVID WORKSTATION, enhancing pharmacy automation and compliance [1][4] - The financial results for the nine months ended September 30, 2025, showed a slight decline in total revenues, primarily due to decreased revenues from Bioprocessing Systems Operations [8][12] Business Highlights - The introduction of AI capabilities in the VIVID WORKSTATION is expected to redefine innovation in pharmacy automation, leading to cost efficiencies for customers [4] - The company achieved a 27% year-over-year sales increase for VIVID products [6] - The DOTS MPS Platform was enhanced with single-use nanoparticles for baffled flasks, indicating ongoing innovation in bioprocessing solutions [6] Financial Overview - For Q3 2025, net revenues increased by $69,600 to $1,404,000, driven by the Torbal Division's performance [6] - Gross profit for Q3 2025 was $638,600, resulting in a gross margin of 45.5%, down from 51.0% in the prior year [9][20] - Operating expenses decreased by $84,800 to $2,160,900 for Q3 2025, reflecting cost reductions in Bioprocessing Systems Operations [10] Income Statement Highlights - The company reported a net income of $3,994,400 for Q3 2025, compared to a net loss of $1,180,100 in Q3 2024 [12][20] - Earnings per share for Q3 2025 were $0.34, a significant improvement from a loss of $(0.11) per share in the same period last year [12][21] - Total other income for Q3 2025 was $5,526,900, primarily due to a gain on the sale of the Genie Division [11][20]

Core Insights - Scientific Industries, Inc. reported a 52.2% increase in net revenues for Q3 2025, reaching $1.404 million compared to $1.334 million in Q3 2024, driven by strong performance in the Torbal Division [6][8] - The company launched an AI-powered feature for its VIVID WORKSTATION, enhancing pharmacy automation and compliance [4][6] - The divestiture of the Genie brand portfolio has allowed the company to focus on high-growth segments, particularly in pill counting [4] Business Highlights - The Torbal Division experienced a 15% year-over-year sales increase, contributing significantly to overall revenue growth [6][8] - VIVID products saw a 27% year-over-year sales increase, indicating strong market demand [6] - The company introduced a new prescription label documentation and verification feature for the VIVID WORKSTATION, utilizing AI technology [6] Financial Overview - For the nine months ended September 30, 2025, net revenues decreased by 2.5% to $3.427 million from $3.515 million in the prior year, primarily due to decreased revenues in Bioprocessing Systems Operations [8] - Gross profit for Q3 2025 was $0.639 million, with a gross margin of 45.5%, down from 51.0% in Q3 2024 [6][9] - The company reported a net income of $3.994 million for Q3 2025, a significant turnaround from a net loss of $1.180 million in Q3 2024 [12][23] Management Commentary - The CEO emphasized the importance of continuous innovation across hardware, firmware, and software to maintain leadership in automated pill counting solutions [4] - The Chairman highlighted the introduction of a new dissolved oxygen sensor for baffled flasks, which has led to new customer wins and improved experimental reproducibility [5] - Despite challenges such as tariffs and reduced government funding affecting customer budgets, the company remains optimistic about future growth [5]

Core Insights - Scientific Industries, Inc. reported a 5% revenue growth in its Benchtop Lab Equipment Operations for Q1 2025, driven by the Genie and Torbal Divisions, with a notable increase in US-based customers [4][5][6] - Overall revenue for the first quarter decreased by 3% due to a significant decline in international sales, which fell by 33% [4][6] - The company secured $1.5 million in equity financing and reported a decreased net loss of $1.78 million, improving from a loss of $2.05 million in the same period last year [5][9] Financial Overview - Net revenues for Q1 2025 totaled $2.41 million, down from $2.48 million in Q1 2024, primarily due to a $182,600 decrease in Bioprocessing Systems Operations revenues [6][17] - Benchtop Laboratory Equipment revenues increased to $2.3 million, a 5% rise compared to $2.2 million in the prior year [5][17] - Bioprocessing Systems Operations revenues decreased by 58% to $133,500 from $316,100 in the previous year [5][17] Profitability Metrics - Gross profit for Q1 2025 was $1.02 million, slightly down from $1.04 million in Q1 2024, with a gross margin of 42.2%, up from 41.9% [7][17] - Operating expenses decreased by 9.7% to $2.83 million, attributed to cost-cutting measures implemented in fiscal 2024 [8][17] - The company reported a basic and diluted loss per share of $0.16, an improvement from $0.20 in the same quarter last year [9][17] Strategic Developments - The company is planning to scale its DOTS platform with the launch of a new optical pH sensor and high-performance liquid injection system in the second half of 2025 [4] - A peer-reviewed publication validated the DOTS Multiparameter platform, confirming its sensitivity and reliability compared to industry standards [4][5]